RINVOQ Trademark

Trademark Overview

On Wednesday, February 1, 2017, a trademark application was filed for RINVOQ with the United States Patent and Trademark Office. The USPTO has given the RINVOQ trademark a serial number of 87320921. The federal status of this trademark filing is REGISTERED as of Tuesday, November 12, 2019. This trademark is owned by AbbVie Biotechnology Ltd.. The RINVOQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
rinvoq

General Information

Serial Number87320921
Word MarkRINVOQ
Filing DateWednesday, February 1, 2017
Status700 - REGISTERED
Status DateTuesday, November 12, 2019
Registration Number5908540
Registration DateTuesday, November 12, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 6, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 6, 2017
Primary Code005
First Use Anywhere DateFriday, August 16, 2019
First Use In Commerce DateFriday, August 16, 2019

Trademark Owner History

Party NameAbbVie Biotechnology Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressPembroke HM11
BM
Party NameAbbVie Biotechnology Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressHamilton HM11
BM
Party NameAbbVie Biotechnology Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressHamilton HM11
BM

Trademark Events

Event DateEvent Description
Saturday, February 4, 2017NEW APPLICATION ENTERED
Monday, February 6, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 27, 2017ASSIGNED TO EXAMINER
Thursday, May 4, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 17, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 6, 2017PUBLISHED FOR OPPOSITION
Tuesday, June 6, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 1, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 23, 2018SOU TEAS EXTENSION RECEIVED
Tuesday, January 23, 2018SOU EXTENSION 1 FILED
Tuesday, January 23, 2018SOU EXTENSION 1 GRANTED
Thursday, January 25, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 30, 2018SOU TEAS EXTENSION RECEIVED
Monday, July 30, 2018SOU EXTENSION 2 FILED
Monday, July 30, 2018SOU EXTENSION 2 GRANTED
Wednesday, August 1, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 31, 2019SOU TEAS EXTENSION RECEIVED
Thursday, January 31, 2019SOU EXTENSION 3 FILED
Thursday, January 31, 2019SOU EXTENSION 3 GRANTED
Saturday, February 2, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 25, 2019SOU TEAS EXTENSION RECEIVED
Thursday, July 25, 2019SOU EXTENSION 4 FILED
Thursday, July 25, 2019SOU EXTENSION 4 GRANTED
Saturday, July 27, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 29, 2019TEAS STATEMENT OF USE RECEIVED
Saturday, September 21, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, August 29, 2019USE AMENDMENT FILED
Saturday, September 21, 2019STATEMENT OF USE PROCESSING COMPLETE
Wednesday, October 9, 2019ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, October 10, 2019NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, November 12, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, November 12, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Thursday, October 30, 2025TEAS SECTION 8 & 15 RECEIVED

Related Keywords

rinvoq gastrointestinal hormonal neurological respiratory ophthalmic dermatological psychiatric diseases disorders related